Edition:
United Kingdom

Boston Scientific Corp (BSX.N)

BSX.N on New York Stock Exchange

27.40USD
18 Jan 2018
Change (% chg)

$0.15 (+0.55%)
Prev Close
$27.25
Open
$27.26
Day's High
$27.50
Day's Low
$27.10
Volume
1,907,130
Avg. Vol
1,986,339
52-wk High
$29.92
52-wk Low
$23.30

Chart for

About

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health,... (more)

Overall

Beta: 1.03
Market Cap(Mil.): $40,477.75
Shares Outstanding(Mil.): 1,372.13
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 149.42 16.58
EPS (TTM): -- -- --
ROI: -- 9.44 10.60
ROE: -- 14.88 14.19

BRIEF-Boston Scientific Receives U.S. FDA Approval For Spectra Wavewriter Spinal Cord Stimulator System

* BOSTON SCIENTIFIC RECEIVES U.S. FDA APPROVAL FOR SPECTRA WAVEWRITER™ SPINAL CORD STIMULATOR SYSTEM Source text for Eikon: Further company coverage:

11 Jan 2018

BRIEF-Boston Scientific Announces Preliminary Unaudited Sales For Q4 and FY17

* BOSTON SCIENTIFIC ANNOUNCES PRELIMINARY UNAUDITED SALES FOR THE FOURTH QUARTER AND FULL YEAR ENDED DECEMBER 31, 2017

09 Jan 2018

BRIEF-Boston Scientific Receives FDA Approval For Vercise Deep Brain Stimulation System

* BOSTON SCIENTIFIC RECEIVES U.S. FDA APPROVAL FOR THE VERCISE™ DEEP BRAIN STIMULATION SYSTEM

11 Dec 2017

BRIEF-Appaloosa LP cuts share stake in BofA, dissolves share stake in Wells Fargo and Activision Blizzard

* Appaloosa LP dissolves share stake in Activision Blizzard Inc - SEC filing

14 Nov 2017

Boston Scientific dips as pacemaker sales disappoint

U.S. medical device maker Boston Scientific Corp's shares fell 5 percent on Thursday after disappointing sales in its pacemaker business, even as the company reported better-than-expected revenue overall in the third quarter.

26 Oct 2017

UPDATE 2-Boston Scientific dips as pacemaker sales disappoint

Oct 26 U.S. medical device maker Boston Scientific Corp's shares fell 5 percent on Thursday after disappointing sales in its pacemaker business, even as the company reported better-than-expected revenue overall in the third quarter.

26 Oct 2017

BRIEF-Boston Scientific announces results for third quarter 2017

* Q3 earnings per share view $0.31 -- Thomson Reuters I/B/E/S

26 Oct 2017

Boston Scientific's profit rises 24 pct in 3rd quarter

Oct 26 U.S. medical device maker Boston Scientific Corp's profit rose 24 percent in the third quarter, driven by growth across all its businesses.

26 Oct 2017

BRIEF-Boston Scientific appoints Desiree Ralls-Morrison general counsel and corporate secretary

* Boston scientific appoints Desiree Ralls-Morrison general counsel and corporate secretary Source text for Eikon: Further company coverage:

04 Oct 2017

BRIEF-Boston Scientific to buy Apama Medical

* Boston Scientific announces agreement to acquire Apama Medical

02 Oct 2017

Competitors

Earnings vs. Estimates